NASDAQ:REGNRegeneron Pharmaceuticals Stock Price, Forecast & News

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, REGN stock has increased by 35.0% and is now trading at $627.54. View which stocks have been most impacted by Coronavirus.

27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 12 hold ratings, 14 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals will be holding an earnings conference call on Wednesday, August 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) released its quarterly earnings results on Tuesday, May, 5th. The biopharmaceutical company reported $6.60 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $6.13 by $0.47. The biopharmaceutical company earned $1.83 billion during the quarter, compared to the consensus estimate of $1.81 billion. Regeneron Pharmaceuticals had a net margin of 28.56% and a return on equity of 24.94%. The company's quarterly revenue was up 6.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.45 earnings per share. View Regeneron Pharmaceuticals' earnings history.

Regeneron Pharmaceuticals announced that its Board of Directors has authorized a stock buyback plan on Tuesday, November 5th 2019, which authorizes the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire up to 2.9% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company's management believes its shares are undervalued.

27 analysts have issued twelve-month price objectives for Regeneron Pharmaceuticals' stock. Their forecasts range from $325.00 to $750.00. On average, they anticipate Regeneron Pharmaceuticals' share price to reach $575.63 in the next year. This suggests that the stock has a possible downside of 8.3%. View analysts' price targets for Regeneron Pharmaceuticals.

News stories about REGN stock have been trending positive on Thursday, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Regeneron Pharmaceuticals earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news about Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 2,470,000 shares, an increase of 24.1% from the June 15th total of 1,990,000 shares. Based on an average trading volume of 1,430,000 shares, the short-interest ratio is presently 1.7 days. Approximately 2.3% of the shares of the stock are short sold. View Regeneron Pharmaceuticals' Current Options Chain.

Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include Gilead Sciences (GILD), Netflix (NFLX), NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Biogen (BIIB), Micron Technology (MU), Walt Disney (DIS), Alphabet (GOOG) and Johnson & Johnson (JNJ).

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include DNB Asset Management AS (0.07%), Envestnet Asset Management Inc. (0.06%), Hexavest Inc. (0.03%), State of Alaska Department of Revenue (0.03%), MERIAN GLOBAL INVESTORS UK Ltd (0.03%) and International Biotechnology Trust PLC (0.01%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Sanofi. View institutional ownership trends for Regeneron Pharmaceuticals.

REGN stock was sold by a variety of institutional investors in the last quarter, including Veracity Capital LLC, Jacobs & Co. CA, IFM Investors Pty Ltd, Carroll Financial Associates Inc., BKD Wealth Advisors LLC, Nelson Van Denburg & Campbell Wealth Management Group LLC, Howland Capital Management LLC, and HBW Advisory Services LLC. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry, and Sanofi. View insider buying and selling activity for Regeneron Pharmaceuticals.

REGN stock was bought by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, State of Alaska Department of Revenue, International Biotechnology Trust PLC, DNB Asset Management AS, Central Bank & Trust Co., Envestnet Asset Management Inc., Patton Fund Management Inc., and Canandaigua National Corp. View insider buying and selling activity for Regeneron Pharmaceuticals.

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of REGN stock can currently be purchased for approximately $627.54.

Regeneron Pharmaceuticals has a market capitalization of $69.04 billion and generates $7.86 billion in revenue each year. The biopharmaceutical company earns $2.12 billion in net income (profit) each year or $21.47 on an earnings per share basis. Regeneron Pharmaceuticals employs 8,100 workers across the globe.

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]